34 RNA Markers: A Breakthrough in Early Alzheimer’s Prediction
The Alzheimer’s field is witnessing a transformative shift, particularly as over 11,000 experts gather at the international Alzheimer Conference AAIC 2026 in London this July. The spotlight is on innovative blood tests aimed at early detection and therapies that extend beyond traditional antibody treatments.
Roche and Novo Nordisk: New Insights into Alzheimer’s Treatment
The pipeline for Alzheimer’s medications is expanding. Roche is unveiling long-term data for its drug Trontinemab at the conference, along with the design of the Phase-III study named “PrevenTRON.” This novel treatment is designed to reduce ARIA-related side effects—these are brain swellings that often plagued earlier antibody therapies.
Novo Nordisk is also making waves as it presents Phase-III data regarding Semaglutide for Alzheimer’s. Meanwhile, Biogen is advancing its Phase-III study for Diranersen, focusing on a technique called “Tau-Silencing.” This multifaceted effort shows the growing diversity of approaches in combating Alzheimer’s.
NewAmsterdam Pharma is sharing promising results from its Phase-III trial “BROADWAY” for Obicetrapib, which showed a significant reduction in the p-tau217 biomarker in over 1,500 patients. With two antibody therapies now available in Germany, that’s an estimated 120,000 patients who might benefit.
Shifting Focus: Dementia with Lewy Bodies
Beyond Alzheimer’s, attention is turning to Dementia with Lewy Bodies (DLB). CervoMed recently released results showing that Neflamapimod can decelerate clinical decline and reduce atrophy in the basal forebrain, marking a step toward Phase-III approval with the FDA.
Precision Blood Tests: Over 90% Accuracy
A significant trend is the move away from invasive diagnostic methods. Modern p-Tau217 blood tests are achieving over 90% accuracy, with Roche already offering a CE-certified test for both primary and secondary healthcare.
The role of artificial intelligence is also becoming crucial in diagnosis. For instance, Neurophet has introduced an AI-supported imaging analysis platform capable of evaluating MRI and PET scans. Partnerships like the one between ALZAI Health and Centauri Health Solutions aim to provide AI-driven risk assessments to about 60 million Medicare Advantage plan enrollees.
Identifying Alzheimer’s Risk Decades in Advance
Research is increasingly suggesting that Alzheimer’s risk can be identified much earlier than previously thought. A recent study has identified 34 RNA markers in blood that can predict Alzheimer’s risk up to 34 years before clinical onset.
Moreover, retinal scans analyzed with AI are emerging as promising biological sensors. They may reveal cumulative risk factors such as hypertension and insomnia, enhancing early detection capabilities.
Existing Medications: Unexpected Impacts on Alzheimer’s Risk
Research is now exploring how existing medications may influence dementia risk. A study conducted by the National Institutes of Health revealed significant findings: SGLT2 inhibitors can reduce risk by 43%, while GLP-1 agonists do so by 33%. Conversely, long-term use of proton pump inhibitors (PPIs) may increase Alzheimer’s risk by up to 44%.
Focusing on the Brain’s Immune Response
Further exploration is taking place regarding the brain’s immune responses. A study involving individuals over 55 found that the BCG vaccine might improve the clearance of beta-amyloid by modulating immune cell reactivity.
Research teams are also investigating the role of Toll-like receptor 10 in microglia cells as a potential “inflammatory brake,” which could pave the way for innovative therapies against neurodegeneration.
The Gut-Brain Axis: A New Area of Interest
The gut-brain axis is gaining attention as well. The gut metabolite Urolithin B is being studied for its antioxidant properties and its ability to inhibit protein aggregations, suggesting a preventive approach to Alzheimer’s.
The Barcelonaβeta Brain Research Center (BBRC) is submitting over 30 contributions focused on Alzheimer’s prevention—a testament to the close interlinking of biomarker research and preventive strategies moving forward.
As researchers deepen their understanding of Alzheimer’s through these numerous avenues, the hope for effective early intervention grows. Stay informed about the latest research, and consider how these breakthroughs might change the way we approach Alzheimer’s prevention and treatment.
